Cited by 192Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentHormonal and reproductive studies

The DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index.

The role of androgens and the androgen receptor in prostate cancer.

Debes, Jose D, Tindall, Donald J·2002·Cancer Letters

DOI 10.1016/s0304-3835(02)00413-5

Open this paper in CoChat — free account

Abstract

Prostate cancer (PCa) is the leading diagnosed malignancy in men in western countries. The relationship between androgens and the androgen receptor (AR) has been studied extensively in PCa. Plasma levels of androgens show variations between different populations, and in many cases this correlates with PCa susceptibility. Indeed, exposure of the fetus to higher androgen concentrations appears to be a risk factor for PCa. The AR is present in the majority of PCa, and its activation by androgens leads to different proliferative, apoptotic and angiogenic events. These events are in turn mediated by dysregulation of cyclin-dependent kinases, apoptotic factors and even mutations in the AR. Although androgen ablation has been the mainstay non-surgical treatment for this disease, most tumors will eventually become refractory to treatment. Different cellular mechanisms appear to be involved in the androgen-independent progression of PCa, including cytokine and growth factor-mediated activation of the AR as well as neuroendocrine differentiation. Thus, an understanding of the cellular mechanisms involved in androgen action may lead to better therapeutic targets for PCa.

Integrity signals

Registry

Crossref · 10.1016/s0304-3835(02)00413-5

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cancer statistics, 2000
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Campbell's urology
Walsh, M. P. C. (1986) · Cited by 3,466
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E. L., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,992
STUDIES ON PROSTATIC CANCER
Huggins, C. (1941) · Archives of Surgery · doi:10.1001/archsurg.1941.01210140043004 · Cited by 1,694
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,243
The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function
Chamberlain, N. L., Driver, E. D., & Miesfeld, R. L. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.15.3181 · Cited by 1,149
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
Čulig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., & Klocker, H. (1994) · PubMed · Cited by 938
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391504 · Cited by 859
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin, M., Bubley, G. J., Ko, Y., Small, E. J., Upton, M. P., Rajeshkumar, B. R., & Balk, S. P. (1999) · PubMed · Cited by 594

Show all 77 references

Research works printed but not linked: 1

Debes, 2002, Proc. AACR, 43

Sorted by citations

Items 101–192 of 192

Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
Maiorano, B. A., Schinzari, G., Ciardiello, D., Rodriquenz, M. G., Cisternino, A., Tortora, G., & Maiello, E. (2021) · Vaccines · doi:10.3390/vaccines9060623 · Cited by 27
Drivers of Radioresistance in Prostate Cancer
King, L., Bernaitis, N., Christie, D., Chess‐Williams, R., Sellers, D., McDermott, C., Dare, W., & Anoopkumar‐Dukie, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195637 · Cited by 24
Targeting Splicing in Prostate Cancer
Antonopoulou, E., & Ladomery, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051287 · Cited by 23
ZIP kinase plays a crucial role in androgen receptor-mediated transcription
Leister, P., Felten, A., Chasan, A. I., & Scheidtmann, K. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210995 · Cited by 23
GADD45γ: a New Vitamin D-Regulated Gene that Is Antiproliferative in Prostate Cancer Cells
Flores, O., & Burnstein, K. L. (2010) · Endocrinology · doi:10.1210/en.2010-0434 · Cited by 23
Structure–Activity Relationships for the Marine Natural Product Sintokamides: Androgen Receptor N-Terminus Antagonists of Interest for Treatment of Metastatic Castration-Resistant Prostate Cancer
Yan, L., Banuelos, C. A., Mawji, N. R., Patrick, B. O., Sadar, M. D., & Andersen, R. J. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.0c00921 · Cited by 22
Protein Profiling of Rat Ventral Prostate following Chronic Finasteride Administration
Cayatte, C., Pons, C., Guigonis, J., Pizzol, J., Elies, L., Kennel, P., Rouquié, D., Bars, R., Rossi, B., & Samson, M. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m600165-mcp200 · Cited by 22
Chromogranin a staining as a prognostic variable in newly diagnosed Gleason score 7-10 prostate cancer treated with definitive radiotherapy
Krauss, D. J., Amin, M., Stone, B. M., Ye, H., Hayek, S., Cotant, M. B., Hafron, J. M., & Brabbins, D. S. (2013) · The Prostate · doi:10.1002/pros.22771 · Cited by 21
Mitogenic Action of the Androgen Receptor Sensitizes Prostate Cancer Cells to Taxane-Based Cytotoxic Insult
Hess-Wilson, J. K., Daly, H. K., Zagórski, W., Montville, C. P., & Knudsen, K. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2249 · Cited by 21
Endocrinotherapy resistance of prostate and breast cancer: Importance of the NF‑κB pathway (Review)
Wang, X., Yao, F., Sun, W., Xu, Z., Zhang, Y., Wei, X., Ding, X., & Xu, Y. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4990 · Cited by 20
Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones
Marklund, M., Schultz, N., Friedrich, S., Berglund, E., Tarish, F., Tanoglidi, A., Liu, Y., Bergenstråhle, L., Erickson, A. M., Helleday, T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33069-3 · Cited by 19
Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome
Qiu, X., Brown, L. G., Conner, J. L., Nguyen, H. M., Boufaied, N., Alaiwi, S. A., Seo, J.-H., Zarif, T. E., Bell, C. A., O’Connor, E. P., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157164 · Cited by 18
Androgen receptor primes prostate cancer cells to apoptosis through down-regulation of basal p21 expression
Lin, Y.-T., Lu, Z., Kokontis, J. M., & Xiang, J. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.10.135 · Cited by 18
Small ubiquitin-like modifier protein-specific protease 1 and prostate cancer
Zuo, Y., & Cheng, J. (2008) · Asian Journal of Andrology · doi:10.1038/aja.2008.45 · Cited by 18
Altered insulin sensitivity, insulin secretion and lipid profile in non-diabetic prostate carcinoma
Nandeesha, H., Koner, B. C., & Dorairajan, L. N. (2008) · Acta Physiologica Hungarica · doi:10.1556/aphysiol.95.2008.1.7 · Cited by 18
Differential expression of AP-1 transcription factors in human prostate LNCaP and PC-3 cells: role of Fra-1 in transition to CRPC status
Kavya, K., Kumar, M. N., Patil, R. H., Hegde, S. M., Kumar, K. M. K., Nagesh, R., Babu, R. L., Ramesh, G. T., & Sharma, S. C. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3012-2 · Cited by 17
Discovery of a novel long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
Ta, H. Q., Whitworth, H., Yin, Y., Conaway, M. R., Frierson, H. F., Campbell, M. J., Raj, G. V., & Gioeli, D. G. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1039-6 · Cited by 17
Sequencing the transcriptional network of androgen receptor in prostate cancer
Chng, K. R., & Cheung, E. C. W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.009 · Cited by 16
Molecular Cloning of a New Gene Which Is Differentially Expressed in Breast and Prostate Cancers
Yousef, G. M., o, C. A. B. N., Michael, I. P., Davidian, C., Stephan, C., Jung, K., & Diamandis, E. P. (2004) · Tumor Biology · doi:10.1159/000079144 · Cited by 16
Biology and natural history of prostate cancer and the role of chemoprevention
Rosenberg, M. T., Froehner, M., Albala, D., & Miner, M. M. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02541.x · Cited by 15
Association of anti‐inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice
Mateus, P. A. M., Kido, L. A., Silva, R. S., Cagnon, V. H. A., & Montico, F. (2018) · The Prostate · doi:10.1002/pros.23758 · Cited by 14
Identification and Characterization of MEL-3, a Novel AR Antagonist That Suppresses Prostate Cancer Cell Growth
Helsen, C., Marchand, A., Chaltin, P., Munck, S., Voet, A. R. D., Verstuyf, A., & Claessens, F. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0763 · Cited by 13
Combination therapies with Wnt signaling inhibition: A better choice for prostate cancer treatment
Hou, Y., Zhao, Z., Li, P., Cao, Y., Zhang, Y., Guo, C., Nie, X., & Hou, J. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189186 · Cited by 12
Dose effect of soy supplementation in prostate cancer: A pilot study
Veldhuizen, P. J. V., Thrasher, J. F., Ray, G., Cherian, R., Ward, J., Holzbeierlein, J. M., Gutow, S., & Banerjee, S. K. (2006) · Oncology Reports · doi:10.3892/or.16.6.1221 · Cited by 12
A Phase I Study of Paclitaxel/Doxorubicin/Thalidomide in Patients with Androgen-Independent Prostate Cancer
Amato, R. J., & Sarao, H. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.n.008 · Cited by 12
Integrated, Molecular Engineering Approaches to Develop Prostate Cancer Gene Therapy
Wu, L., & Sato, M. (2003) · Current Gene Therapy · doi:10.2174/1566523034578230 · Cited by 12
Radionuclide Therapy of Painful Bone Metastases—A Comparative Study Between Consecutive Radionuclide Infusions, Combination With Chemotherapy, and Radionuclide Infusions Alone
Sideras, P. A., Stavraka, A., Gouliamos, A., & Limouris, G. S. (2012) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909112469719 · Cited by 11
Identification of androgen‐responsive genes that are alternatively regulated in androgen‐dependent and androgen‐independent rat prostate tumors
Pfundt, R., Smit, F. P., Jansen, C., Aalders, T. W., Straatman, H., van der Vliet, W., Isaacs, J. T., van Kessel, A. G., & Schalken, J. A. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20184 · Cited by 11
Network pharmacology and transcriptomics reveal androgen receptor as a potential protein target for 6PPD-quinone
Liao, X.-L., Zhou, J.-M., Wang, Y., Chen, Z., & Cai, Z. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.177678 · Cited by 10
Prevention of Prostate Cancer: What We Know and Where We Are Going
Jayachandran, J., & Freedland, S. J. (2008) · American Journal of Men s Health · doi:10.1177/1557988307313918 · Cited by 9
Efecto de los compuestos bioactivos de algunos alimentos en la salud
Urango, L. A., Parra, G. A. M., Quiroz, M. A. C., Henao, D. C., Zapata, P. A., Mira, L. L., Castaño, E., López, A., Vanegas, C. V., Loaiza, M. C., et al. (2011) · Perspectivas en Nutrición Humana · doi:10.17533/udea.penh.9389 · Cited by 8
Prognostic significance of focal neuroendocrine differentiation in prostate cancer: Cases with autopsy-verified cause of death
Tarján, M. (2010) · Indian Journal of Urology · doi:10.4103/0970-1591.60442 · Cited by 8
Androgen metabolic genes in prostate cancer predisposition and progression
Makridakis, N. M. (2005) · Frontiers in bioscience · doi:10.2741/1745 · Cited by 8
Phloretin in Benign Prostate Hyperplasia and Prostate Cancer: A Contemporary Systematic Review
Yang, C., Ou, Y., Lin, C., Lin, Y., Tung, M., Yu, C., Lin, J., & Wen, C. (2022) · Life · doi:10.3390/life12071029 · Cited by 7
Androgen therapy reverses injuries caused by ethanol consumption in the prostate: Testosterone as a possible target to ethanol-related disorders
Mendes, L. D. O., Scarano, W. R., Rochel-Maia, S. S., Fioruci‐Fontaneli, B. A., Chuffa, L. G. D. A., Anselmo-Franci, J. A., & Martinez, F. E. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.11.003 · Cited by 7
Rhenium-188 Generator-Based Radiopharmaceuticals for Therapy
Knapp, F. F., Kropp, J., & Liepe, K. (2012) · Medical radiology · doi:10.1007/174_2012_669 · Cited by 6
Genetic polymorphisms in the androgen metabolism pathway and risk of prostate cancer in low incidence Malaysian ethnic groups.
Poniah, P., Mohamed, Z., Apalasamy, Y. D., Zain, S. M., Kuppusamy, S., & Razack, A. H. A. (2015) · PubMed Central · Cited by 6
May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate.
Sabet, A., Khalaf, F., Mahjoob, S., Zreiqat, A. A., Biersack, H., & Ezziddin, S. (2013) · Europe PMC (PubMed Central) · Cited by 6
The androgen clock is an epigenetic predictor of long-term male hormone exposure
Sugrue, V. J., Prescott, M., Glendining, K. A., Bond, D. M., Horvath, S., Anderson, G. M., Garratt, M., Campbell, R. E., & Hore, T. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2420087121 · Cited by 4
Secondary Hormonal Manipulation
Merseburger, A. S., Belka, C., Behmenburg, K., & Stenzl, A. (2008) · KARGER eBooks · doi:10.1159/000139883 · Cited by 5
Rarity of DNA sequence alterations in the promoter region of the human androgen receptor gene
Cabral, D. F., Santos, A. O., Ribeiro, M. L., Mesquita, J. C., Carvalho-Salles, A. B., & Hackel, C. (2004) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2004001200004 · Cited by 5
Testosterone as a prospective predictor of pathological Gleason score and pathological stage in prostate cancer
Drobková, H., Jurečeková, J., Grendár, M., Kliment, J., Halášová, E., & Kliment, J. (2017) · General Physiology and Biophysics · doi:10.4149/gpb_2017044 · Cited by 4
Impact of maternal and postnatal zinc dietary status on the prostate of pubescent and adult rats
Camora, L. F., Silva, A. P. G., dos Santos, S. A. A., Justulin, L. A., Perobelli, J. E., Barbisan, L. F., & Scarano, W. R. (2017) · Cell Biology International · doi:10.1002/cbin.10756 · Cited by 4
Efficacy of zoledronic acid for the elimination of disseminated tumor cells in a clinically relevant, spontaneously metastatic prostate cancer xenograft model
Boeckelmann, L., Freytag, V., Ahlers, A., Maar, H., Gosau, T., Baranowsky, A., Schmitz, R., Pantel, K., Schumacher, U., Haider, M., et al. (2023) · Bone · doi:10.1016/j.bone.2023.116741 · Cited by 5
Meta-Analysis of steroid-converting enzymes and related receptors in prostate cancer suggesting novel combined therapies
Zhang, W., Li, T., & Lin, S. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105559 · Cited by 4
A current role status of micro-ultrasound imaging in prostate cancer diagnosis
Grynkiewicz, M., & Wiewióra, M. (2023) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-232024 · Cited by 2
Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance
Karanika, S., Karantanos, T., Yin, J., Li, L., & Thompson, T. C. (2014) · Asian journal of urology · doi:10.1016/j.ajur.2015.04.004 · Cited by 2
Combination of Multiple Markers Predicts Prostate Cancer Outcome
Menon, M. A. S. R. (2015) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.1000213 · Cited by 2
Association between Statin Use and Clinical Outcomes in Patients with De Novo Metastatic Prostate Cancer: A Propensity Score-weighted Analysis
Chen, T. S., Liu, H., Chang, Y., Chuang, Y., Chen, Y.-T., Su, Y., Huang, C., Wu, Y.-T., Wang, H., & Luo, H. (2024) · The World Journal of Men s Health · doi:10.5534/wjmh.230155 · Cited by 2
The Biology of Aging and the Development of Lower Urinary Tract Dysfunction and Disease
Macoska, J. A., Kasina, S., Campeau, L., & Andersson, K. (2014) · Springer eBooks · doi:10.1007/978-1-4614-9047-0_2 · Cited by 2
Prostate Cancer Markers
Finlay, J. A., Mikolajczyk, S. D., Pribyl, T. M., Wallace, R. B., & Rittenhouse, H. G. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-791-8_7 · Cited by 2
The Potential Roles of Seeds and Seed Bioactives on the Prevention and Treatment of Breast and Prostate Cancer
Power, K. A., & Thompson, L. U. (2010) · Springer eBooks · doi:10.1007/978-90-481-9800-9_8 · Cited by 1
Determination of Six Transmembrane Protein of Prostate 2 Gene Expression and Intracellular Localization in Prostate Cancer
İrer, B., Demir, Ö., Kéfi, A., & Aslan, G. (2017) · Bulletin of Urooncology · doi:10.4274/uob.890 · Cited by 1
Genetic and Non-Genetic Risk Factors in Prostate Cancer: Towards a Precision Medicine Approach
Hloušek, S., Argalácsová, S., Soukupová, J., Záleský, M., Jurok, M., & Vočka, M. (2025) · Folia Biologica · doi:10.14712/fb2025071030095 · Cited by 1
Tributyltin Protumorigenic Effects Targeting Prostate Cancer Cell Metabolism, Proliferation, Migration, and Invasion
Feijó, M., Brás, L. A., Serra, C. D. M., Fonseca, L. R. S., Correia, S., Pereira, B. J., Duarte, A. P., Cardoso, H. J., Vaz, C. V., & Socorro, S. (2026) · Environmental Toxicology · doi:10.1002/tox.70029 · Cited by 1
Mechanistic insights and molecular therapy for neuroendocrine prostate cancer
Niu, Y., Zhang, S., Zhang, S., Tao, J., & Zhu, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1806742 · Cited by 1
Prostate Cancer Screening with PSA
Thesis, D., & Carlsson, S. (2010) · Cited by 1
Expression of HER2, EGFR, CD44, PPARγ and AR in Salivary Cancer
Mori, T., Kunimura, T., MATUO, K., OCHIAI, Y., Date, H., Sugiyama, T., Saito, K., Ohike, N., & Morohoshi, T. (2010) · The Showa University Journal of Medical Sciences · doi:10.15369/sujms.22.171 · Cited by 1
Yeast-based evolutionary modeling of androgen receptor mutations and natural selection
Zhang, H., Zhang, L., Chen, S., Yao, M., Ma, Z., & Yuan, Y. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010518 · Cited by 1
Lack of effect of human c‐Ha‐ras proto‐oncogene overexpression on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats
Hokaiwado, N., Asamoto, M., Cho, Y., Tsuda, H., & Shirai, T. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01398.x · Cited by 1
Activins, Inhibins, and Bone Morphogenetic Proteins as Modulators and Biomarkers of Prostate Cancer Progression
Hayashida, T., Gupta, V., Thiagalingam, S., & Maheswaran, S. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-292-2_22 · Cited by 1
Nuevos blancos moleculares en el cáncer de próstata
Moiola, C. P. (2012) · Repositorio Digital Institucional de la Universidad de Buenos Aires (Universidad de Buenos Aires)
Intracrine regulation of androgen receptor in prostate cancer
Dillard, P. (2010) · Atlanta University Center Robert W. Woodruff Library (Atlanta University Center Robert W. Woodruff Library)
唾液腺導管癌4例でのHER2, EGFR, ARの発現の検討
智昭, 森., 俊和, 嶋., 金井, 英., 哲弥, 門., 雅子, 寺., & 武幸, 三. (2012) · 口腔・咽頭科 = Stomato-pharyngology · doi:10.14821/stomatopharyngology.25.207
Bioactive compounds on food and health-promoting properties
Urango, L. A., Parra, G. A. M., Quiroz, M. A. C., Henao, D. C. T., Zapata, P. A., Mira, L. L., Castaño, E., López, A., Vanegas, C. V., Loaiza, M. C., et al. (2009) · Perspectivas en Nutrición Humana
Adipocyte-Induced Inflammation In Prostate Tumor Progression In Bone: Role Of Cxcr2 And Osteopontin
Hardaway, A. (2015) · Human Biology
Prostate Cancer Related Gene Analysis Based on Literature Mining
Yang, J., Wang, J., & He, T. (2011) · International Conference on Bioinformatics and Biomedical Engineering · doi:10.1109/icbbe.2011.5780136
Nuevas estrategias terapéuticas para el cáncer de próstata
Zalazar, F. (2015) · Repositorio Digital Institucional de la Universidad de Buenos Aires (Universidad de Buenos Aires)
MOLECULAR DETERMINANTS OF ANDROGEN ACTION
Santti, H. (2004) · Työväentutkimus Vuosikirja
Genetic analysis of Mild Androgen Insensitivity Syndrome (MAIS) and breast cancer in a South African Indian family
Chauhan, S. (2015)
The Role of EGFR, HER 2-4, Heregulin and Downstream Signalling in Prostate Adenocarcinoma
Grimsley, S. J. S. (2008) · Enlighten: Theses (The University of Glasgow)
Expressão de receptores androgenicos no lobulo ventral da prostata do gerbilo da Mongolia
Cordeiro, R. S. (2007) · doi:10.47749/t/unicamp.2007.399010
WITHDRAWN: Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance
Karanika, S., Karantanos, T., Yin, J., Li, L., & Thompson, T. C. (2014) · Asian journal of urology · doi:10.1016/j.ajur.2014.09.002
Histopathological Investigation of Nuclear Y-box Binding Protein-1 Expression in Salivary Gland Carcinoma
Mihashi, H. (2016) · Practica oto-rhino-laryngologica Suppl · doi:10.5631/jibirinsuppl.147.102
Restoration of the glycoconjugates expression in the ventral prostateof androgen-deprived mice by dihydrotestosterone: A glycohistochemical study
Akif, F., & Genten, F. (2016) · International journal of innovation and applied studies
Gene Regulation of The Human Pregnane-X Receptor Gene.
Aouabdi, S. (2005) · Surrey Research Insight Open Access (The University of Surrey)
Androgen Mediated Regulation of VEGF in Prostate Cancer
Eisermann, K. (2011) · OhioLink ETD Center (Ohio Library and Information Network)
Molecular heterogeneity of prostate cancer bone metastasis
Ylitalo, E. B. (2018)
Efeito do lincRNA PVT1 associado ao potenciador de zeste homólogo 2 (EZH2) e ao receptor de andrógeno (AR) sobre a expressão gênica em larga escala em células LNCaP de câncer de próstata
Videira, A. (2019) · doi:10.11606/t.46.2019.tde-24102019-104009
Delineating the role of Hepatocyte Nuclear Factor 1 Beta (HNF1B) transcript variants in prostate cancer
Chandra, S. (2020) · Queensland University of Technology · doi:10.5204/thesis.eprints.135713
Erratum: Analytical and compositional aspects of isoflavones in food and their biological effects
(2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700478
Histopathological Investigation of Nuclear Y-box Binding Protein-1 Expression in Salivary Gland Carcinoma
Mihashi, H. (2016) · Practica Oto-Rhino-Laryngologica · doi:10.5631/jibirin.109.349
17 Prostaatcarcinoom
van der Heide, W. K., & van der Meer, K. (2009) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-7249-2_17
Diffuse Synaptophysin Expression in Aggressive Recurrent Castration-Resistant Acinar (Usual) Prostate Cancer: Case Report and Review of Prostatic Neuroendocrine Tumors
Russell, D. H., & Mignano, S. E. (2020) · AJSP Review and Reports · doi:10.1097/pcr.0000000000000354
Role of Iroquois homeobox 4 (IRX4) isoforms in prostate cancer
Vitharanage, A. (2023) · Queensland University of Technology · doi:10.5204/thesis.eprints.242137
Flavones and prostate cancer
Das, S., Sen, K., Sinha, K., Roy, D., & Sil, P. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21842-2.00008-5
Additional file 3 of PVT1 signals an androgen-dependent transcriptional repression program in prostate cancer cells and a set of the repressed genes predicts high-risk tumors
Videira, A., Beckedorff, F., daSilva, L. F., & Verjovski‐Almeida, S. (2021) · Figshare · doi:10.6084/m9.figshare.13558765
Additional file 2 of PVT1 signals an androgen-dependent transcriptional repression program in prostate cancer cells and a set of the repressed genes predicts high-risk tumors
Videira, A., Beckedorff, F., daSilva, L. F., & Verjovski‐Almeida, S. (2021) · Figshare · doi:10.6084/m9.figshare.13558762
Obesogens in Prostate Cancer: An Endocrine and Metabolic Threat
Feijó, M., Fonseca, L. R. S., Kiss‐Toth, E., Socorro, S., & Correia, S. T. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00690-y
L'analyse des mécanismes d'action d'Hsp27 a mis en évidence TCTP comme nouvelle cible thérapeutique des cancers de la prostate résistants à la castration.
Baylot, V. (2013) · theses.fr (ABES) · doi:10.70675/47b727faz4a37z46c2z9f5dz29201400c39b
BindingDB Entry 50013809: Structure-Activity Relationships for the Marine Natural Product Sintokamides: Androgen Receptor N-Terminus Antagonists of Interest for Treatment of Metastatic Castration-Resistant Prostate Cancer.
BindingDB (2022) · UC San Diego · doi:10.7270/q2cv4nhr
Carcinogenese experimental no lobulo ventral da prostata do geribo da Mongolia
Zanetoni, C. (2007) · doi:10.47749/t/unicamp.2007.408039

Authors: Debes, J. D., & Tindall, D. J.
Affiliations: Mayo Clinic (US)
Corresponding author: Tindall, Donald J
Venue: Cancer Letters
Publisher: Elsevier BV
Published: 2002-12
Volume: 187
Issue: 1-2
Pages: 1-7
ISSN: 0304-3835 (ISSN-L)
DOI: 10.1016/s0304-3835(02)00413-5
OpenAlex: W2141562227
Cited by: 191
References: 77
Citations by year: 2026: 3 · 2025: 4 · 2024: 4 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 4 · 2017: 10 · 2016: 5 · 2015: 7 · 2014: 7 · 2013: 8 · 2012: 10
FWCI: 3.08
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Cancer Letters (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA 91956, P50CA091956)
National Institute of Diabetes and Digestive and Kidney Diseases (DK60920, R01DK060920)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords: prostate cancer, androgens, androgen receptor, androgen receptor mutations, androgen-independent progression, androgen deprivation therapy, neuroendocrine differentiation, cyclin-dependent kinases, apoptosis, angiogenesis, prenatal androgen exposure, therapeutic target
MeSH terms: Androgens, Humans, Male, Neoplasms, Hormone-Dependent, Prostate, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The role of androgens and the androgen receptor in prostate cancer.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks